Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genmab
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
Dose-escalating and cohort expansion safety trial of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known to express tissue factor
• To establish the tolerability of HuMax-TF-ADC dosed three times q4wk in a mixed population of patients with specified solid tumors
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma
The primary objective of this trial is to explore the efficacy of HuMax-CD4 treatment with respect to tumor response and duration in patients with refractory or relapsed non-cutaneous CD4+ T-cell lymp...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more disease modifying anti-rheumatic drugs
Part A: To evaluate the safety of HuMax-CD20 in patients with active rheumatoid arthritis. Part B: To evaluate the efficacy of HuMax-CD20 in patients with active rheumatoid arthritis using the America...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer Patients
To demonstrate that treatment with zalutumumab in combination with chemo-radiation is superior to chemo-radiation alone in terms of progression free survival in treatment naïve stage IIIA–IIIB NSCLC p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genmab
Update Il y a 4 ans
Genmab Hx-CD20-406 : Essai de phase 3 évaluant l’efficacité d’un traitement par ofatumumab chez des patients ayant une leucémie lymphocytaire à grandes cellules B. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell chronic lymphocytic leukemia who have failed fludarabine and alemtuz...
Country
France
organs
Leucémies chroniques
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have failed standard platinum-based chemotherapy
To investigate if HuMax-EGFr in combination with Best Supportive Care (BSC) is superior to BSC in terms of overall survival in non-curable patients with recurrent and/or metastatic disease who have fa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN
To determine key pharmacokinetic parameters for zalutumumab as monotherapy in patients with SCCHN.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Genmab
Update Il y a 4 ans
Genmab GEN204 : Essai de phase 2 randomisé évaluant l'efficacité et la tolérance d'un traitement par radiochimiothérapie associée ou non à du zalutumumab, chez des patients ayant un cancer du poumon non à petites cellules. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A Randomized, Open-Label, Multi-Center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
,
Radiothérapie et Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with Radiotherapy, in Patients with Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum based Chemotherapy
To evaluate the safety of repeat dosing and establish the maximum tolerated dose (MTD) of zalutumumab in combination with radiotherapy in patients with stage III, IVa or IVb locally advanced squamous ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genmab A/S
Update Il y a 4 ans
A Dose-Escalation, Randomized Phase I/II trial of Zalutumumab - a Human Monoclonal Anti-EGF receptor Antibody - With or Without Irinotecan chemotherapy in Cetuximab refractory Colorectal Cancer patients Who Have Failed Standard Chemotherapy and Progressed During or Within 6 months of Stopping Cetuximab-Based Therapy
Primary Objective Part 1 • Evaluate the safety of escalating dose of zalutumumab in combination with irinotecan in patients with colorectal cancer (CRC) who have failed previous standard chemotherapy...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
Next